The shortage of generic chemotherapy drugs cisplatin and carboplatin that began in early 2023 did not increase short-term ...

Citi launched its coverage of Cytokinetics (NASDAQ:CYTK) with a Buy recommendation, noting that the cardiac drug developer’s recent selloff is overdone given that its lead asset, aficamten, which has ...

For the second legislative session in a row, Sen. Willie Preston is pushing to ban several chemicals from Illinois food items ...

Iterum Therapeutics PLC (NASDAQ:ITRM) reported its fourth-quarter 2024 financial results, revealing a narrower-than-expected loss. The company posted an actual EPS of -0.12, beating the forecasted EPS ...